Action MGRX MANGOCEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Mangoceuticals, Inc.

Actions

MGRX

US56270V1061

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 14/06/2024 		Varia. 5j. Varia. 1 janv.
0,3199 USD -5,94% Graphique intraday de Mangoceuticals, Inc. -25,64% +15,53%
06/06 Le brevet de Mangoceuticals approuvé pour les soins préventifs en Australie MT
06/06 Mangoceuticals, Inc. reçoit un avis d'acceptation pour une demande de brevet en Australie pour une technologie relative aux maladies respiratoires et aux soins préventifs CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Mangoceuticals Patent Approved for Preventive Care in Australia
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
Mangorx to Introduce ?Mojo? Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
Top Midday Gainers
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
Mangoceuticals, Inc. to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MGRX
  4. Actualités Mangoceuticals, Inc.
  5. Autres langues